Nakamura, Seigo

Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial

Yamauchi, H., Toi, M., Takayama, S., Nakamura, S., Takano, T., Cui, K., Campbell, C., De Vos, L., Geyer, C., & Tutt, A. (2023) · Breast Cancer

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 13